The Consequences of Using Prescription Medicine for Heartburn (Long Term)

Thank you to Drs. Quinn Rivet (ND) and David Lescheid (ND) for their excellent article found in the Vital Link.  They have provided some good background and the research behind some of the known consequences of long term PPI (Proton Pump Inhibitors, a.k.a acid blockers) usage.

If you are looking for natural ways to get over heartburn, click here  to get your free ebook and extra help.

PPIs do have usefulness short-term and for some people, long-term use may be advisable.  However, the risks of continuing on these drugs should be known.  Here is the list:

  • Bone fractures
    • This likely due to the fact that proteins, which make up the matrix of the bone will not be digested well due to low acid along with decreased calcium absorption.
  • Stomach tumors (cancerous and benign)
    • The cells that signal  other cells to create acid via gastrin secretion) do not get blocked and they make more and more gastrin and grow and enlarge.  This ultimately causes the heartburn rebound when attempting to discontinue PPIs.
  • Loss of stomach function (with scarring and cellular changes), known as atrophic gastritis
  • Heart attacks
  • Congitive decline/dementia (in the elderly population)
  • Kidney disease, kidney failure
  • Cardiac disease
  • Metabolic disease
  • Celiac diseae
  • Pneumonia
  • Muscle disease
  • C. difficile infection
    • A strong acid bath is an important first step in preventing pathogens from invading and colonizing the gut.  Without this, harmful bacteria can thrive and cause infections.
  • Many of the above increased risks are likely related to decreased absorption of many nutrients.

Below is a list of some scholarly articles (research) on of the conditions associated with long term PPI use.

  • Cai D, Feng W, Jian G.  Acid-suppressive medications and risk of fracture: an updated meta-analysis.  Int J Clin Exp Med.  2015; 8 (6): 8893-8904
  • Ko Y, Tany J et al.  Safety of proton pump inhibitors and risk of gastric cancers: review of literature and pathophysiological mechanisms.  Expert Opin Drug Saf.  2015; 15(1): 53-63
  • Song H, Zhu J, Lu D. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions.  Cochrane Database Syst Rev.  2014 Dec.:(12):CD010623
  • Nasser SC, Slim M et al.  Influence of proton pump inhibitors on gastritis diagnosis and pathological gastric changes. World J Gastroenterol. 2015;21(15):4599-4606
  • Hagiwara T, Mukaisho K et al.  Proton pump inhibitors and helicobacter pylori-assoiated pathogenesis.  Asian Pac J Cancer Prev.  2015; 16(4): 1315-1319
  • Shah HG, LePendu P et al.  Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population.  PLoS One.  2015;10(8);e0124653
  • Haenisch B, von Holt K et al.  Risk of dementia in elderly patients with the use of proton pump inhibitors.  Eur Arch Psychiatry Clin Neurosci. 2015; 265(5):419-28
  • Akter S, Hassan MR et al.  Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB saftware.  Alzheimers Res Ther. 2015;7:79
  • Tran-Duy A, Spaetgens B et al.  Use of Proton Pump Inhibitors and Risks of Fundic Gland Polyps and Gastric Cancer:  Systematic Review and Meta-analysis.  Clin Gastroenterol Hepatol. 2016; 14(12)1706-1719.
  • Martin FC, Chenevix-Trench G, Yeomans ND.  Systematic review with meta0analysis: fundic gland polyps and proton pump inhibitors.  Aliment Pharmacol Ther.  2016; 44(9):915-925
  • Arora P, Gupta A et al.  Proton pump inhibitors are associated with increased risk of development of chronic kideny disease.  BMC Nephrol.  2016; 171)112
  • Lazarus B, Chen Y et al.  Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.  JAMA Intern Med.  2016; 176(2):238-246
  • Xie Y, Bowe B et al.  Proton Pump Inhibitors and Risk of Inicident CKD and Progression to ESRD.  J Am Soc Nephrol.  2016; 27(10):3153-3163
  • Delcher A, Hily S et al.  Multimorbidities and Overprescription of Proton Pump Inhibitor in Older Patients.  PLoS One. 2015;10(11): e0141779
  • Lebwohl B, Sechler SJ et al.  Use of proton inhibitors and subsequent risk of celia disease. Dig Liver Dis.  2014;46(1):226-40
  • Eom CS, Jeon CY et al.  Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis.  CMAJ. 2011; 183(3):310-319
  • Herzig SJ, Howell MD et al.  Acid-suppressive medication use and the risk for hospital acquire pneumonia.  JAMA.  2009; 301(20):2120-2128
  • Colmenares EW, Pappas AL.  Proton Pump Inhibitors: Risk for Myopathy?  Ann Pharmacother. 2016 Aug 18.  Pii:1060028016665641 {Epub ahead of print}
  • Clark DW, Strandell J.  Myopathy including polymyosisit: a likely class adverse effect of proton pump inhibitors? Eur J Clin Pharamcol.  2006; 62(6): 473-47
  • **The above has been taken directly out of:  Rivet Q, Lescheid D.  Proton Pump Inhibitors:  Their Effect on the Microbiome and Beyond.  Vital Link. 2016; 239(2): 9-17.

Leave A Comment...